Our team will be tracking the latest breakthroughs and clinical updates shaping thoracic oncology. Planning your conference coverage or need strategic intelligence from WCLC? Start with our ONCrg planner. ONCrg is anticipating: • Data on novel therapies in NSCLC patient subsets with high unmet need: • First Phase III data for zipalertinib in 1L EGFR […]
Excerpt from Custom Post Type Indication: CVAC
Executive Summary: ONCrg analysts Robert Williams and Amanda Cook preview the highest-impact clinical presentations at ASCO 2026 across pancreatic, non-small cell lung, prostate, multiple myeloma, and NHL — covering the context of each readout, how the treatment landscape is expected to shift, and the specific signals the analyst team will be watching for on the floor.
Potential game changers: Late-stage readouts at ASCO/EHA: Selinexor: The last of the wave of novel MOA + ruxolitinib pivotal trials in frontline myelofibrosis (MF). All in this wave have faced struggles, selinexor included, with a missed symptom endpoint in Phase III SENTRY. Detailed outcomes reported at ASCO will inform not only the next steps for selinexor, but future development in the field of first-line MF as a whole.
Executive Summary: ONCrg’s PhD analysts review the most significant early-stage oncology developments from AACR 2026 and preview key data expected at ASCO, covering cell therapies, antibody-drug conjugates (ADCs), immuno-oncology, and the DNA damage response (DDR) space.
Oncology Resource Group goes beyond the abstracts to discuss what really happened at AACR 2026.
Excerpt from Custom Post Type Indication: ECS